Dividend Declaration, Technical Updates, Upcoming Earnings and Conference, Expansion of Portfolio, and Court's Ruling - Research Reports on Apache, Emerge Energy, Mattel, Parkway and GSK

NEW YORK, September 26, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Apache Corporation (NYSE: APA), Emerge Energy Services LP (NYSE: EMES), Mattel, Inc. (NASDAQ: MAT), Parkway Properties Inc. (NYSE: PKY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6784-100free.

--
Apache Corporation Research Reports
On September 18, 2014, Apache Corporation (Apache) announced that the Company's Board of Directors has declared a cash dividend of $0.25 per share on the Company's common shares, payable on November 21, 2014, to stockholders of record on October 22, 2014. The full research reports on Apache are available to download free of charge at:

http://www.analystsreview.com/Sep-26-2014/APA/report.pdf

--
Emerge Energy Services LP Research Reports
On September 23, 2014, shares in Emerge Energy Services LP (Emerge Energy) declined 7.11% to close the trading session at $110.98, extending its losses from previous trading session. Emerge Energy's stock opened the session at $117.30 and fluctuated between $107.75 and $119.20. The stock recorded a trading volume of 1.36 million shares, significantly higher than its 30-day average volume of 0.54 million shares. Over the past three months, the stock has returned 10.97%, outperforming the S&P 500, which returned 1.68% over the same period of time. The full research reports on Emerge Energy are available to download free of charge at:

http://www.analystsreview.com/Sep-26-2014/EMES/report.pdf

--
Mattel, Inc. Research Reports
On September 23, 2014, Mattel, Inc. (Mattel) announced that the Company plans to release its Q3 2014 financial results on October 16, 2014 at approx. 6:00 a.m. ET. Following the results release, Bryan G. Stockton, CEO, and Kevin Farr, CFO will host a conference call and webcast at 8:30 a.m. ET on the same day. According to analysts polled by Bloomberg Businessweek, the Company is expected to report Q3 2014 EPS of $1.04 on revenues of $2.2 billion. In addition, Mattel's senior management will provide an update on the business to securities analysts through a presentation on October 30, 2014 at 9:00 a.m. ET. Both the events will be broadcasted live on the Company's official website. The full research reports on Mattel are available to download free of charge at:

http://www.analystsreview.com/Sep-26-2014/MAT/report.pdf

--
Parkway Properties Inc. Research Reports
On September 22, 2014, Parkway Properties Inc. (Parkway) announced that the Company has reached an agreement with HFF Inc. to acquire three Class A office properties located in the Westshore submarket of Tampa, Florida. Corporate Center I, II, and III at International Plaza, which are adjacent to Parkway's Corporate Center IV at International Plaza, total approximately 974,000 square feet. As a part of the same agreement, the Company has also agreed to purchase 19 additional office properties located in six states aggregating nearly 2.1 million square feet. The Company plans to sell these additional properties either concurrently with, or within 12 months after, the acquisition of the Corporate Center assets, as these assets are not consistent with the Company's current investment strategy. The gross purchase price of entire portfolio of properties is $475.0 million. The Company expects to close this transaction in Q4 2014, subject to customary closing conditions. Parkway estimates initial full-year cash net operating income yield from these assets in the range of 5.7% - 6.0%, after adjusting initial full-year contractual rent concessions. The full research reports on Parkway are available to download free of charge at:

http://www.analystsreview.com/Sep-26-2014/PKY/report.pdf

--
GlaxoSmithKline plc Research Reports
On September 19, 2014, GlaxoSmithKline plc (GSK) reported that the Changsha Intermediate People's Court in Hunan Province, China has ruled that its subsidiary GSK China Investment Co. Ltd (GSKCI) had offered money or property to non-government personnel in order to obtain improper commercial gains, and has been found the Company guilty of bribing non-government personnel. The Company informed that the court's decision follows investigations initiated by China's Ministry of Public Security in June 2013. Consequently, the court has ordered GSKCI to pay a fine of £297 million (approximately RMB3 billion) to the Chinese government. GSK said that it will include the associated costs and charges related to restructuring in its Q3 2014 update. GSK CEO, Sir Andrew Witty, said, "Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this." The full research reports on GSK are available to download free of charge at:

http://www.analystsreview.com/Sep-26-2014/GSK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED